Tag
The FDA has rejected Sydnexis’s low-dose atropine eye drop SYD-101 for controlling childhood myopia progression despite promising trial results, highlighting challenges in demonstrating long-term efficacy and clinical significance in
This study compares atropine and cyclopentolate for cycloplegia in preschoolers, finding atropine leads to less myopic refraction and may reduce premyopia overestimation. It highlights implications for precise refractive diagnosis in young
A recent randomized clinical trial demonstrates that diversified segmental defocus optimization (DSDO) spectacle lenses significantly reduce the onset and progression of myopia in children, with or without adjunct low-dose atropine.
